Companion Diagnostic Market, Global Outlook
and Forecast 2022-
2028 Market
Oncology Companion Diagnostic Market, Global Outlook and Forecast 2022-2028 Market Scope: Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Oncology Companion Diagnostic Market, Global Outlook and Forecast 2022-2028 Market Size and Growth
The Oncology Companion Diagnostic Market is projected to reach $10.5 billion by 2028, growing at a CAGR of 15.6% during the forecast period. Factors driving market growth include increasing cancer prevalence, advancements in precision medicine, and the rising demand for personalized treatment options. The market is expected to witness significant growth globally. Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Agilent Technologies, Inc.
◍ Illumina, Inc.
◍ Qiagen N.V.
◍ Thermo Fisher Scientific Inc.
◍ F. Hoffmann-La Roche Ltd.
◍ ARUP Laboratories
◍ Abbott
◍ Myriad Genetics, Inc.
◍ bioMérieux SA
◍ Invivoscribe, Inc.
The global oncology companion diagnostic market is highly competitive with key players like Agilent Technologies, Illumina, Qiagen, Thermo Fisher Scientific, Roche, ARUP Laboratories, Abbott, Myriad Genetics, bioMérieux, and Invivoscribe. These companies offer innovative diagnostic solutions to drive market growth. Sales revenue: Roche $32.2 billion, Thermo Fisher Scientific $35.1 billion, Illumina $4.2 billion.
Market Segmentation
By Application
◍ Hospital
◍ Pathology/Diagnostic Laboratory
◍ Academic Medical Center
By Product
◍ Polymerase Chain Reaction (PCR)
◍ Next-Generation Sequencing (NGS)
◍ Immunohistochemistry (IHC)
◍ In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
◍ Others
Request Sample Report
Market Growth
Request Sample Report
$ X Billion USD
